NL-OMON27565尚未招募不适用
Effects of Verapamil versus metoprolol to prevent progression from Paroxysmal to persistent Atrial Fibrillation
Martini ziekenhuis Groningen0 个研究点目标入组 200 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •In order to be eligible to participate in this trial, a subject must meet all of the following criteria:
- •Patients (age > 18) with symptomatic paroxysmal AF with an indication for rate control medication who participate in the RACE 5 registry. Patients must be able and willing to sign informed consent for the randomised study.
排除标准
- •Exclusion criteria are (history of) persistent AF, previous adverse effects to the study drugs, contra-indication for the study drugs (i.e. heart failure with reduced ejection fraction, symptomatic hypotension, atrioventricular conduction disturbance, severe asthma/COPD), history of pulmonary vein isolation (PVI), pregnancy and breastfeeding.
研究者
相似试验
撤回
4 期
Effects of VERApamil versus metoprolol to prevent progression from Paroxysmal to persistent Atrial Fibrillatioatrial fibrillationNL-OMON44431Martini Ziekenhuis200
已完成
3 期
Effective of verapamil combination with vacuum for treatment of peyronie's diseasePeyronie disease.Disorder of penis, unspecifiedN48.9IRCT20200316046786N1Ahvaz University of Medical Sciences30
招募中
Unknown
The therapeutic effect of verapamil and triamcinolone along with macroneedling in the treatment of Peyronie's plaquePeyronie's plaque.N48.6Peyronie's diseaseIRCT20230408057854N1Shahid Beheshti University of Medical Sciences64
招募中
2 期
Comparing the prophylaxis effects of Metoprolol and Magnesium on prevention of AFatrial fibrillation after CABG ( coronary artery bypass graft)atrial fibrillation.Other specified complications of cardiac and vascular prosthetic devices, implants and graftsIRCT2016031520258N5Vice chancellor for research, Arak University of Medical Sciences195
进行中（未招募）
1 期
Treatment effects of Bisoprolol and Verapamil in symptomatic patients with non-obstructive hypertrophic cardiomyopathyon-obstructive hypertrophic cardiomyopathyCTIS2024-515346-17-00Aarhus Universitetshospital140